J. F. van Poorten, K. Dhasmana, R. Kuypers
Feb 1, 1984
Citations
0
Influential Citations
41
Citations
Quality indicators
Journal
Anesthesia and analgesia
Abstract
Recently, vecuronium bromide (Nomon, Org NC45) has been introduced in clinical practice as an intermediate-duration nondepolarizing neuromuscular blocking agent. A number of experimental and clinical studies have shown that vecuronium bromide has no significant effects on the cardiovascular and autonomic nervous systems (14). Unlike pancuronium bromide, vecuronium has a short duration of neuromuscular blocking action, a predictable recovery time, and no cumulative effects (2,5). The neuromuscular blocking effect of vecuronium can be readily antagonized by neostigmine (6). Furthermore, the elimination of vecuronium is less dependent on renal function than is elimination of pancuronium (7,8). Vecuronium bromide fulfills nearly all the criteria of an ideal nondepolarizing neuromuscular blocking agent. Although not completely unexpected, problems with phannacologic antagonism and reversal of the neuromuscular blockade produced by vecuronium may arise. The present case report deals with the prolonged effect of vecuronium bromide in a patient with renal insufficiency treated for supraventricular tachycardia with the calcium entry blocker verapamil.